首页> 外文期刊>Herz >Cardioband (R): Where do we stand, who are suitable patients?
【24h】

Cardioband (R): Where do we stand, who are suitable patients?

机译:cardioband(r):我们在哪里,谁是合适的患者?

获取原文
获取原文并翻译 | 示例
           

摘要

Functional mitral regurgitation (FMR) is characterized by a dilatation of the mitral valve annulus resulting in an insufficient adaptation of the anterior and posterior mitral valve leaflets and/or severe tethering of the leaflets due to dilatation of the left ventricle. The Cardioband (R) system was introduced in 2015 and is a catheter-based direct mitral valve annuloplasty procedure for treatment of FMR. In the European CE approval study 60 patients with moderate or severe FMR were analyzed per protocol. There were no device or procedure-related deaths. The technical success rate of the procedure, defined as successful implantation and tightening was 97%. At 1 year, the overall survival and survival free of hospital readmission for heart failure were 87% and 66%, respectively. Currently, various interventional treatment procedures are available, such as the edge-to-edge technique as well as direct and indirect annuloplasty. In summary, patients with FMR as a result of a dilatation of the mitral valve annulus appear to be suitable for direct annuloplasty with the Cardioband (R) system.
机译:功能二尖瓣反流(FMR)的特征在于,引起二尖瓣环的扩张,导致对左心室扩张引起的前二尖瓣叶和/或叶片的严重束缚的不足。 Cardioband系统于2015年引入,是一种基于导管的直接二尖瓣环形成形术,用于治疗FMR。在欧洲CE批准研究中,每方案分析60例中度或严重的FMR患者。没有设备或与程序相关的死亡。该程序的技术成功率,定义为成功的植入和收紧率为97%。 1年,没有医院心力衰竭入院存活的整体存活和生存率分别为87%和66%。目前,各种介入治疗程序可用,例如边缘到边缘技术以及直接和间接的环形成形术。总之,由于二尖瓣环扩张导致具有FMR的患者似乎适用于具有Cardioband系统的直接渐环成形术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号